RxDoctor Payments Data

Ronald Howard, MD

Neurology · Naples, FLNPI 1316940976

Payments from drug & device makers

$15,773in general payments, 2019–2025

Across 755 payments — averaging $20.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Eisai Inc.$1K
  • GE HealthCare$1K
  • UCB, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Amgen$757
  • plus $6K from 39 others

What the payments were for

  • Speaking & faculty fees$1,90012%
  • Travel & lodging$390%
  • Food & beverage$13,59286%
  • Education$2291%
  • Gifts$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,773 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$400,971
Medicare patients
805
Services billed
13,589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine20$164,571
Nurtec OdtRimegepant Sulfate17$34,839
BotoxOnabotulinumtoxina30$33,399
RytaryCarbidopa/Levodopa18$32,361
Memantine Hcl ErMemantine Hcl274$23,012
Lacosamide13$8,744
BelsomraSuvorexant17$8,193
EliquisApixaban11$6,994
SuboxoneBuprenorphine Hcl/Naloxone Hcl17$6,696
ButransBuprenorphine12$6,629
Rivastigmine36$6,257
Pyridostigmine Bromide17$5,852
Ropinirole ErRopinirole Hcl18$5,175
DayvigoLemborexant14$4,390
Memantine Hcl158$3,680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$1,156$164,57120 claims
PfizerNurtec Odt, Eliquis$176$41,83328 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$159$38,21335 claims
AbbVieBotox$4,173$33,39930 claims
Eisai Inc.Dayvigo$1,412$4,39014 claims
Upsher-smith Laboratories LLCTopiramate$29$71044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,434 neurology providers in Florida.

Other neurology in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →